

February 9, 2026

| | |
|--|--|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|--|--|

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500038, Telangana, India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721211
Email: ir@aurobindo.com

Hyderabad, India, February 09th, 2026: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUOPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended December 31, 2025.

Aurobindo Pharma Limited Q3FY26

| Amount (INR Cr) | Q3 FY26 | Q3 FY25 | %Change YoY | Q2 FY26 | %Change QoQ |
|---|---------|---------|-------------|---------|-------------|
| Revenue from Operations | 8,646 | 7,979 | 8.4% | 8,286 | 4.3% |
| EBITDA before R&D | 2,163 | 2,056 | 5.2% | 2,064 | 4.8% |
| EBITDA margin before R&D | 25.0% | 25.8% | -75 bps | 24.9% | 10 bps |
| EBITDA before Forex and Other Income and exceptional item | 1,773 | 1,628 | 9.0% | 1,678 | 5.7% |
| EBITDA Margin (%) | 20.5% | 20.4% | 11 bps | 20.3% | 26 bps |
| PBT before share of P/L of JV | 1,338 | 1,198 | 11.7% | 1,274 | 5.0% |
| Net Profit for the period | 910 | 846 | 7.6% | 848 | 7.3% |

Key Highlights of Q3FY26

- Revenue from Operations increased by 8.4% YoY to INR 8,646 Cr with growth in Europe and ARV
- US formulations revenue increased by 2.2% YoY to INR 3,739 Cr (USD 420 million)
- Europe formulations revenue increased by 27.4% YoY to INR 2,703 Cr (EUR 261 million)
- Growth Markets revenue remained flat YoY at INR 865 Cr (USD 97 million)
- ARV revenue increased by 22.4% YoY to INR 376 Cr (USD 42 million)
- EBITDA before R&D stood at INR 2,163 crores with a margin of 25.0%
- EBITDA before Forex and Other Income stood at INR 1,773 Cr; EBITDA margin at 20.5%
- Research & Development (R&D including depreciation) spend was INR 409 Cr, 4.7% of revenues
- Received final approval for 7 ANDAs from the USFDA (including 2 ANDAs previously tentatively approved now receiving final approval)
- Net Profit for the period stood at INR 910 Cr. (inclusive of one-time cost due to change in labour code of ₹65 Cr)
- Strong net cash position as on 31-Dec-25 after appropriating cash for acquisition of Khandelwal laboratories is at USD 251mn
- Free Cashflows of \$118mn generated during the quarter
- Basic & Diluted EPS stood at INR 15.67 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "Q3 reflected steady execution across Aurobindo's core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the U.S. and Europe. Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability. As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term."



Q3FY26: Operational Performance (Consolidated)

| ₹ Cr | Q3FY26 | Q3FY25 | Y-o-Y (%) | Q2FY26 | Q-o-Q (%) |
|--------------------------------|--------------|--------------|--------------|--------------|-------------|
| USA | 3,739 | 3,658 | 2.2% | 3,638 | 2.8% |
| Europe | 2,703 | 2,121 | 27.4% | 2,480 | 9.0% |
| Growth Markets* | 865 | 873 | -0.9% | 882 | -1.9% |
| ARV | 376 | 307 | 22.4% | 325 | 15.5% |
| Total Formulations | 7,683 | 6,960 | 10.4% | 7,325 | 4.9% |
| Beta-lactam | 686 | 722 | -4.9% | 668 | 2.7% |
| Non Beta-lactam | 277 | 284 | -2.6% | 292 | -5.4% |
| Total API | 963 | 1,006 | -4.3% | 961 | 0.2% |
| Puerto Rico | - | 13 | - | - | - |
| Revenue from operations | 8,646 | 7,979 | 8.4% | 8,286 | 4.3% |

*Includes domestic formulation sales of INR 74 Cr in Q3FY26 against INR 81 Cr in Q2 FY26

Q3FY26: Consolidated Revenue Breakup - Geography & Business Wise

Q3FY26



Q3FY26: Business Area Wise Performance

Formulations revenue increased by 10.4% YoY to INR 7,683 Cr.

US Formulations

- US revenue increased by 2.2% YoY to INR 3,739 Cr and accounted for 43.2% of consolidated revenue
- Received final approval for 7 ANDAs from the USFDA (including 2 ANDAs previously tentatively approved now receiving final approval)
- As on 31st December 2025, on a cumulative basis, the company has filed 879 ANDAs with USFDA and received 719 final approvals and 31 tentative approvals
- The company has launched 9 products during the quarter

Europe Formulations

- Europe revenue increased by 27.4% YoY to INR 2,703 Cr driven by robust performance across all key markets; and accounted for 31.3% of consolidated revenue
- In Euro terms, revenue increased by 10.7% YoY to EUR 261 million

Growth Markets Formulations

- Growth Markets formulations revenue remained flat YoY at INR 865 Cr driven by good performance in key markets; and accounted for 10.0% of consolidated revenue
- In USD terms, revenue decreased by 6.1% YoY to USD 97 million
- Domestic formulation sales for the quarter stood at INR 74 Cr, 9MFY26 Domestic formulations revenues stood at 226 Cr

ARV Formulations

- ARV business revenue increased by 22.4% YoY to INR 376 Cr accounting for 4.3% of consolidated revenue
- In USD terms, revenue increased by 16.1% YoY to USD 42 million

Active Pharmaceutical Ingredients (API)

- API revenues decreased by 4.3% Y-o-Y to INR 963 Cr contributing to 11.1% of consolidated revenue
- In USD terms, revenue decreased by 9.2% to USD 108 million

Q3FY26: Global Regulatory Filings

| Details | Q3FY26 | Cumulative Filings as on 31 st Dec 2025 |
|---|--------|--|
| US ANDAs (including filings from Aurobindo USA) | 2 | 879 |
| US DMFs (including filings from Eugia and Auro Peptides) | 4 | 315 |
| Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada) | 61 | 4,967 |
| API filings in other key regulated markets (incl. multiple registrations) | 17 | 4,075 |

Q3FY26: Final USFDA Approvals Received

Received by Aurobindo Pharma Limited

| # | Product | Strength | Therapy Area |
|---|---|---|---|
| 1 | Linagliptin Tablets (FTF) | 5 mg | Anti-Diabetic |
| 2 | Cariprazine Capsules (FTF) | 1.5 mg, 3 mg and 6 mg | Central Nervous System |
| 3 | Naproxen Oral Suspension USP | 125 mg/5 mL | Pain Relief |
| 4 | Fosfomycin Tromethamine Granules for Oral Solution | 3 grams | Anti-Infective |
| 5 | Pseudoephedrine Hydrochloride Extended-Release Tablets USP (OTC) | 240 mg | Anti-Histamine |
| 6 | Potassium Chloride Oral Solution USP | 10% (20 mEq/15 ml) and 20% (40 mEq/15 ml) | Electrolyte Replacement, Nutritional Supplement |
| 7 | Loperamide Hydrochloride Capsules USP (Soft Gelatin Capsules) (OTC) | 2 mg | Gastrointestinal |

Q3FY26: Earnings Call Details

The company will host earnings call at **8.30 AM IST on 10th February 2026**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <https://bit.ly/4rhwkyk>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications

Phone: 040-66721211

Email: ir@aurobindo.com